

Cargo-specific degraders using selective autophagy

Degradation and clearance of disease related intracellular targets by autophagy


Introduction

Autophagy is an intracellular degradation mechanism and is related to a large scale of diseases, e.g. neurodegenerative disease, cancer and metabolic disease. It is a promising approach in drug discovery.

By now, current technologies cannot selectively trigger autophagy targeting specific proteins. This invention established a system to introduce autophagy embracing the target of interest (See the figure below).

PROTAC, a targeted protein degradation technology, is existent but it is a ubiquitin-proteasome system, thus the scope of targeted proteins are limited to soluble intracellular ones. Meanwhile, this invention's system is suitable for aggregated proteins, organelles and pathogens, etc.

This invention: AUTACs (Autophagy-targeting chimeras)





*Please refer to this article:
Takahashi et al., *Molecular Cell*, (2019), 76, p1-14.

Patent Data Sheet


Application No.(Serial No.): PCT/JP2018/3576 (T16-040),
PCT/JP2018/25941 (T16-123)
Inventor: ARIMOTO Hirokazu, ITTO Kaori, TAKAHASHI Daiki

Degradation of fragmented mitochondria by autophagy

[Opal knockdown conditions]



LC3 : Autophagy marker
Hsp60 : Mitochondria
(Merge of these two shows degradation (yellow))



Mitochondrial protein levels are significantly reduced when autophagy occurs.

→ It implies the fragmented mitochondria are degraded.

Contact

Tohoku Techno Arch Co., LTD
TEL:+81-22-222-3049, FAX:+81-22-222-3419
[Click](#) to contact